Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 161 to 170 of 369 total matches.
Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
AND LACTATION — No adequate data
on vadadustat use in pregnant women are available.
Administration of the drug ...
The FDA has approved the hypoxia-inducible factor
prolyl hydroxylase inhibitor (HIF-PHI) vadadustat
(Vafseo – Akebia) for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 3 months. Vadadustat is
the second HIF-PHI to be approved in the US for this
indication; daprodustat (Jesduvroq) was approved
earlier, but it was withdrawn from the US market in
2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9 doi:10.58347/tml.2025.1722b | Show Introduction Hide Introduction
Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
during treatment and for
4 months after the last dose.
No data are available on the effects ...
The alkylating agent lurbinectedin (Zepzelca – Jazz)
has received accelerated approval from the FDA
for treatment of metastatic small-cell lung cancer
(SCLC) in adults with disease progression on or after
platinum-based chemotherapy. Accelerated approval
was based on the overall response rate and duration
of response. About 13-15% of lung cancers are small-cell
cancers. Most SCLCs occur in patients who are
current or former smokers.
Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
death and altered
fetal growth. There are no data on the presence of
olutasidenib in human breast milk ...
Olutasidenib (Rezlidhia – Rigel), an oral isocitrate
dehydrogenase-1 (IDH1) inhibitor, has been
approved by the FDA for treatment of relapsed or
refractory acute myeloid leukemia (AML) in adults
with a susceptible IDH1 mutation. It is the second
drug that targets cancer metabolism to be approved
for this indication; ivosidenib (Tibsovo) was
approved in 2022.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e58-9 doi:10.58347/tml.2023.1673e | Show Introduction Hide Introduction
In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
. There are no data on the presence
of pemigatinib in human breast milk or its effects
on the breastfed infant ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has been approved by the FDA for treatment
of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth
factor receptor 1 (FGFR1) rearrangements. It is the
first targeted therapy to be approved in the US for this
indication. The drug received accelerated approval
from the FDA in 2020 for treatment of adults with
previously treated, unresectable, locally advanced or
metastatic cholangiocarcinoma with FGFR2 fusions
or other rearrangements.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e71-2 doi:10.58347/tml.2023.1674g | Show Introduction Hide Introduction
Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
after the last dose. No data are available on
the presence of eflornithine in human breast milk or
its ...
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine
decarboxylase inhibitor, has been approved by the
FDA to reduce the risk of relapse in children and with
high-risk neuroblastoma who had at least a partial
response to prior multiagent, multimodality therapy,
including anti-GD2 immunotherapy. About 40-50%
of neuroblastoma cases are classified as high-risk
and they account for ~15% of all pediatric cancer
deaths. Eflornithine is the first drug to be approved
to reduce the risk of relapse in children with high-risk
neuroblastoma. Eflornithine was previously available
in the US...
Med Lett Drugs Ther. 2024 May 13;66(1702):e81-2 doi:10.58347/tml.2024.1702f | Show Introduction Hide Introduction
In Brief: A New Indication for Tenecteplase (TNKase)
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
, with higher scores indicating
greater disability) 90–120 days after treatment. At the
time of data cutoff ...
The tissue plasminogen activator (tPA) tenecteplase
(TNKase – Genentech) has been approved by the FDA
for treatment of acute ischemic stroke in adults. It
is the second tPA to be approved in the US for this
indication; alteplase (Activase) was approved in
1996. Tenecteplase was approved in 2000 to reduce
the risk of death associated with acute ST-elevation
myocardial infarction (STEMI).
Med Lett Drugs Ther. 2025 Apr 28;67(1727):71-2 doi:10.58347/tml.2025.1727d | Show Introduction Hide Introduction
Drugs for Alcohol Use Disorder
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
intellectual disability, and
alcohol spectrum disorders in the offspring. Data
on the use of drugs for AUD ...
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 in the past year. The lifetime prevalence of AUD
in the US population has been estimated to be about
30%. Despite this high prevalence and the associated
morbidity, mortality, and costs, only 3 drugs are FDA-approved
for treatment of the disorder.
Ashwagandha Supplements
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
has
been reported to cause miscarriage; it should not be
used during pregnancy. No data are available ...
Ashwagandha is an herb extracted from the roots of
an evergreen shrub (Withania somnifera) found in
India that has been used as a "tonic" for centuries.
No specific constituent has been identified as an
active ingredient. Herbal supplements containing
ashwagandha, which is also known as winter cherry
and Indian ginseng, are widely promoted now in the
US for treatment of pain, anxiety, stress, fatigue, sleep
disturbances, cognitive decline, diabetes, arthritis,
male infertility, and various cancers.
Fluvoxamine for COVID-19?
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
-19, but conclusive data supporting its use
are lacking. A large trial is underway.
1. Treatments ...
A recent article in JAMA and an interview of its senior
author on 60 Minutes have heightened interest in
off-label use of the oral selective serotonin reuptake
inhibitor (SSRI) fluvoxamine (Luvox, and generics) to
treat COVID-19.
Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
(PSMA)-positive metastatic castration-resistant
prostate cancer (mCRPC). Data on efficacy of the
drug ...
The FDA has approved lutetium lu 177 vipivotide
tetraxetan (Pluvicto – Novartis) for treatment of
prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate
cancer (mCRPC) in adults previously treated with
androgen receptor (AR) pathway inhibitors and
taxane-based chemotherapy.